HRP20140413T1 - Spla2 hidrolizirajuä†i liposomi s poboljšanim svojstvima pohranjivanja - Google Patents
Spla2 hidrolizirajuä†i liposomi s poboljšanim svojstvima pohranjivanja Download PDFInfo
- Publication number
- HRP20140413T1 HRP20140413T1 HRP20140413AT HRP20140413T HRP20140413T1 HR P20140413 T1 HRP20140413 T1 HR P20140413T1 HR P20140413A T HRP20140413A T HR P20140413AT HR P20140413 T HRP20140413 T HR P20140413T HR P20140413 T1 HRP20140413 T1 HR P20140413T1
- Authority
- HR
- Croatia
- Prior art keywords
- internal
- external
- concentration
- nacl
- pharmaceutical preparation
- Prior art date
Links
- 239000002502 liposome Substances 0.000 title claims 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 16
- 230000000065 osmolyte Effects 0.000 claims 12
- 239000000825 pharmaceutical preparation Substances 0.000 claims 8
- 239000011780 sodium chloride Substances 0.000 claims 8
- 239000002904 solvent Substances 0.000 claims 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 5
- 229930006000 Sucrose Natural products 0.000 claims 5
- 239000005720 sucrose Substances 0.000 claims 5
- 239000008363 phosphate buffer Substances 0.000 claims 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Dispersion Chemistry (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (8)
1. Farmaceutski pripravak, naznačen time, da sadrži:
- jedan SPLA2-hidrolizirajući liposom, koji sadrži cisplatin, sadržan u liposomu,
- vanjsko otapalo,
- unutarnje otapalo, koje je sadržano u liposomu,
pri čemu je razlika koncentracije osmolita između unutarnjeg i vanjskog otapala (vanjska koncentracija osmolita subtrahirana od unutarnje koncentracije osmolita) iznosi više od 200 mM.
2. Farmaceutski pripravak prema zahtjevu 1, naznačen time, da je cisplatin jedina djelotvorna tvar.
3. Farmaceutski pripravak prema bilo kojem od prethodnih zahtjeva, naznačen time, da je razlika koncentracije osmolita između unutarnjeg i vanjskog otapala (vanjska koncentracija osmolita subtrahirana od unutarnje koncentracije osmolita) iznosi između 200 i 600 mM.
4. Farmaceutski pripravak, prema bilo kojem od prethodnih zahtjeva, naznačen time, da je razlika koncentracije osmolita između unutarnjeg i vanjskog otapala (vanjska koncentracija osmolita subtrahirana od unutarnje koncentracije osmolita) iznosi između 280 i 320 mM.
5. Farmaceutski pripravak, prema zahtjevu 1, naznačen time, da je razlika koncentracije osmolita između unutarnjeg i vanjskog otapala (vanjska koncentracija osmolita subtrahirana od unutarnje koncentracije osmolita) iznosi barem 275 mM.
6. Farmaceutski pripravak, prema bilo kojem od prethodnih zahtjeva, naznačen time, da unutarnja otopina sadrži NaCl ili KCl u koncentraciji između 0,2-2,5 težinskih %.
7. Farmaceutski pripravak, prema bilo kojem od prethodnih zahtjeva, naznačen time, da vanjska otopina sadrži NaCl ili KCl u koncentraciji između 0,2-2,5 težinskih %.
8. Farmaceutski pripravak, prema bilo kojem od prethodnih zahtjeva, naznačen time, da je unutarnja i vanjska otopina odabrana iz skupine, koja se sastoji iz:
a) Unutarnje otopine od 0,8-1,0% NaCl i 9-11% saharoze i vanjskog otapala iz 8-12 mM fosfatnog pufera (pH 6,5) + 9-11% saharoze,
b) Unutarnje otopine iz 1,6-2,0% NaCl i vanjske otopine iz 8-12 mM fosfatnog pufera (pH 6,5) + 9-11% saharoze,
c) Unutarnje otopine iz 0,8-1,0% NaCl i 9-11% saharoze i vanjske otopine iz 8-12 mM fosfatnog pufera (pH 6,5) + 0,35-0,55% NaCl + 4-6% saharoze,
d) Unutarnje otopine iz 1,6-2,0 mM NaCl i vanjske otopine iz 8-12 mM fosfatnog pufera (pH 6,5) + 0,8-1,0% NaCl.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200901150A DK177529B1 (en) | 2009-10-23 | 2009-10-23 | Liposomes with improved storage stability |
| PCT/DK2010/050283 WO2011047689A2 (en) | 2009-10-23 | 2010-10-25 | Liposomes with improved storage stability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140413T1 true HRP20140413T1 (hr) | 2014-07-04 |
Family
ID=43533079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140413AT HRP20140413T1 (hr) | 2009-10-23 | 2014-05-07 | Spla2 hidrolizirajuä†i liposomi s poboljšanim svojstvima pohranjivanja |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9820941B2 (hr) |
| EP (1) | EP2490671B1 (hr) |
| JP (1) | JP5778160B2 (hr) |
| CN (1) | CN102639114B (hr) |
| AU (1) | AU2010310240B2 (hr) |
| CA (1) | CA2772973C (hr) |
| CY (1) | CY1115139T1 (hr) |
| DK (2) | DK177529B1 (hr) |
| ES (1) | ES2465565T3 (hr) |
| HR (1) | HRP20140413T1 (hr) |
| PL (1) | PL2490671T3 (hr) |
| PT (1) | PT2490671E (hr) |
| RS (1) | RS53321B (hr) |
| SI (1) | SI2490671T1 (hr) |
| SM (1) | SMT201400065B (hr) |
| WO (1) | WO2011047689A2 (hr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2123258A1 (en) | 2008-05-23 | 2009-11-25 | Liplasome Pharma A/S | Liposomes for drug delivery |
| DK177532B1 (en) | 2009-09-17 | 2013-09-08 | Bio Bedst Aps | Medical use of sPLA2 hydrolysable liposomes |
| EP2394640A1 (en) | 2010-05-21 | 2011-12-14 | MediGene AG | Improved liposomal formulations of lipophilic compounds |
| JP6263609B2 (ja) * | 2014-04-30 | 2018-01-17 | 富士フイルム株式会社 | リポソーム組成物及びその製造方法 |
| WO2015166987A1 (ja) * | 2014-04-30 | 2015-11-05 | 富士フイルム株式会社 | リポソーム組成物及びその製造方法 |
| DK3138555T3 (da) * | 2014-04-30 | 2020-12-14 | Fujifilm Corp | Liposomsammensætning og fremgangsmåde til fremstilling heraf |
| EP3291797B1 (en) * | 2015-05-04 | 2020-09-02 | Versantis AG | Method for preparing transmembrane ph-gradient vesicles |
| US9725769B1 (en) | 2016-10-07 | 2017-08-08 | Oncology Venture ApS | Methods for predicting drug responsiveness in cancer patients |
| AU2017258901A1 (en) | 2016-12-30 | 2018-07-19 | Allarity Therapeutics Europe ApS | Methods for predicting drug responsiveness in cancer patients |
| AU2019200325A1 (en) * | 2018-01-31 | 2019-08-15 | Liplasome Pharma Aps | Methods for treating cancer and predicting drug responsiveness in cancer patients |
| CN110496103B (zh) * | 2018-05-18 | 2022-05-10 | 上海维洱生物医药科技有限公司 | 一种多西他赛棕榈酸酯脂质体及其制备方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4880635B1 (en) * | 1984-08-08 | 1996-07-02 | Liposome Company | Dehydrated liposomes |
| ATE77051T1 (de) | 1988-03-04 | 1992-06-15 | Takeda Chemical Industries Ltd | Liposom-zusammensetzung. |
| JP2931981B2 (ja) * | 1988-03-04 | 1999-08-09 | 武田薬品工業株式会社 | リポソーム製剤およびその製造法 |
| FI895340A0 (fi) * | 1988-11-14 | 1989-11-09 | Bristol Myers Squibb Co | Hypertonisk cisplatin-loesning. |
| JPH05194192A (ja) * | 1991-08-21 | 1993-08-03 | Shionogi & Co Ltd | 分散性の改善された温度感受性ｍｌｖ型リポソ−ム |
| JPH069374A (ja) * | 1992-04-07 | 1994-01-18 | Banyu Pharmaceut Co Ltd | リポソ−ム製剤およびその製造法 |
| AU3559695A (en) | 1994-09-30 | 1996-04-26 | Inex Pharmaceuticals Corp. | Glycosylated protein-liposome conjugates and methods for their preparation |
| US5858397A (en) | 1995-10-11 | 1999-01-12 | University Of British Columbia | Liposomal formulations of mitoxantrone |
| EP0929293B1 (en) * | 1996-08-23 | 2003-10-22 | Sequus Pharmaceuticals, Inc. | Liposomes containing a cisplatin compound |
| FR2759293B1 (fr) * | 1997-02-11 | 1999-04-30 | Ethypharm Lab Prod Ethiques | Microgranules contenant du cisplatine, procede de fabrication, preparation pharmaceutique et utilisation en polychimiotherapie ou en association avec une radiotherapie |
| ATE277935T1 (de) | 2000-02-10 | 2004-10-15 | Liplasome Pharma As | Auf lipiden basierende systeme zur arzneistoffabgabe |
| ES2280355T3 (es) | 2000-04-12 | 2007-09-16 | Liplasome Pharma A/S | Sistema de administracion de medicamentos basados en lipidos para su utilizacion en la piel. |
| US20030026831A1 (en) | 2001-04-20 | 2003-02-06 | Aparna Lakkaraju | Anionic liposomes for delivery of bioactive agents |
| CA2383259A1 (en) | 2002-04-23 | 2003-10-23 | Celator Technologies Inc. | Synergistic compositions |
| US8518437B2 (en) | 2001-11-13 | 2013-08-27 | Celator Pharmaceuticals, Inc. | Lipid carrier compositions with enhanced blood stability |
| US20040022842A1 (en) | 2002-06-03 | 2004-02-05 | Mebiopharm Co., Ltd. | Liposome preparations containing oxaliplatin |
| WO2005000266A2 (en) | 2003-05-22 | 2005-01-06 | Neopharm, Inc. | Liposomal formulations comprising a combination of two or more active agents |
| GB0312309D0 (en) * | 2003-05-29 | 2003-07-02 | Gaslini Children S Hospital G | Targeted liposome |
| US20070286898A1 (en) | 2004-08-31 | 2007-12-13 | Astellas Pharma Inc. | Intracellular Drug Delivery Improving Liposome |
| WO2006048017A1 (en) | 2004-11-03 | 2006-05-11 | Liplasome Pharma A/S | Lipid-based drug delivery systems containing unnatural phospholipase a2 degradable lipid derivatives and the therapeutic uses thereof |
| TW200726485A (en) | 2005-07-01 | 2007-07-16 | Alza Corp | Liposomal delivery vehicle for hydrophobic drugs |
| CN101040853B (zh) * | 2006-03-22 | 2010-05-12 | 上海医药工业研究院 | 一种草乌甲素多泡脂质体及其制备方法 |
| CA2647779A1 (en) | 2006-03-23 | 2007-09-27 | Liplasome Pharma A/S | Lipid based drug delivery systems comprising phospholipase a2 degradable lipids that perform an intramolecular cyclization reaction upon hydrolysis |
| US20080085295A1 (en) | 2006-07-14 | 2008-04-10 | Fmc Biopolymer As | Hydrogels containing low molecular weight alginates and biostructures made therefrom |
| CN100563646C (zh) * | 2007-07-13 | 2009-12-02 | 陈祥峰 | 一种奥沙利铂脂质体葡萄糖制剂的制备方法 |
| EP2123258A1 (en) * | 2008-05-23 | 2009-11-25 | Liplasome Pharma A/S | Liposomes for drug delivery |
-
2009
- 2009-10-23 DK DKPA200901150A patent/DK177529B1/en not_active IP Right Cessation
-
2010
- 2010-10-25 US US13/503,614 patent/US9820941B2/en active Active
- 2010-10-25 CN CN201080047402.7A patent/CN102639114B/zh active Active
- 2010-10-25 ES ES10772956.8T patent/ES2465565T3/es active Active
- 2010-10-25 CA CA2772973A patent/CA2772973C/en active Active
- 2010-10-25 SI SI201030638T patent/SI2490671T1/sl unknown
- 2010-10-25 WO PCT/DK2010/050283 patent/WO2011047689A2/en active Application Filing
- 2010-10-25 EP EP10772956.8A patent/EP2490671B1/en active Active
- 2010-10-25 PT PT107729568T patent/PT2490671E/pt unknown
- 2010-10-25 PL PL10772956T patent/PL2490671T3/pl unknown
- 2010-10-25 AU AU2010310240A patent/AU2010310240B2/en not_active Ceased
- 2010-10-25 DK DK10772956.8T patent/DK2490671T3/da active
- 2010-10-25 RS RS20140274A patent/RS53321B/en unknown
- 2010-10-25 JP JP2012534543A patent/JP5778160B2/ja active Active
-
2014
- 2014-05-07 HR HRP20140413AT patent/HRP20140413T1/hr unknown
- 2014-05-30 CY CY20141100387T patent/CY1115139T1/el unknown
- 2014-06-05 SM SM201400065T patent/SMT201400065B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK2490671T3 (da) | 2014-06-16 |
| CA2772973A1 (en) | 2011-04-28 |
| RS53321B (en) | 2014-10-31 |
| US9820941B2 (en) | 2017-11-21 |
| US20120219618A1 (en) | 2012-08-30 |
| CA2772973C (en) | 2017-08-15 |
| ES2465565T3 (es) | 2014-06-06 |
| WO2011047689A3 (en) | 2011-11-17 |
| CY1115139T1 (el) | 2016-12-14 |
| DK200901150A (en) | 2011-04-24 |
| AU2010310240B2 (en) | 2015-11-26 |
| AU2010310240A1 (en) | 2012-03-22 |
| JP2013508315A (ja) | 2013-03-07 |
| CN102639114B (zh) | 2015-04-01 |
| WO2011047689A2 (en) | 2011-04-28 |
| DK177529B1 (en) | 2013-09-08 |
| PT2490671E (pt) | 2014-05-30 |
| CN102639114A (zh) | 2012-08-15 |
| PL2490671T3 (pl) | 2014-08-29 |
| EP2490671B1 (en) | 2014-03-05 |
| EP2490671A2 (en) | 2012-08-29 |
| SMT201400065B (it) | 2014-07-07 |
| JP5778160B2 (ja) | 2015-09-16 |
| SI2490671T1 (sl) | 2014-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140413T1 (hr) | Spla2 hidrolizirajuä†i liposomi s poboljšanim svojstvima pohranjivanja | |
| DK2068839T3 (da) | Farmaceutiske sammensætninger omfattende nilotinib eller salt deraf | |
| WO2013179307A3 (en) | Stabilized pharmaceutical compositions of saxagliptin | |
| BR112015012547A2 (pt) | composições de prostaciclina e métodos de sua utilização | |
| EA201270216A1 (ru) | Фармацевтический состав | |
| EA201070421A1 (ru) | Микрорибонуклеиновые кислоты | |
| CL2013000815A1 (es) | Composicion farmaceutica liquida de adm inistracion parenteral que comprende dexmedetomidina o una sal de la misma en una concentracion de 0,005 a 50 µg/ml y adicionalmente comprende cloruro de sodio en una concentracion de 0,01 a 2 % en peso, dispuesta dentro de un contenedor de vidrio sellado. | |
| BR112014009087A2 (pt) | formulações de etanercept estabilizadas com xilitol | |
| EA201490847A1 (ru) | Аминокислотные производные, функционализованные на n конце, способные образовывать микросферы, инкапсулирующие лекарственное средство | |
| WO2009147075A3 (en) | Pharmaceutical compositions containing a crystalline form of posaconazole | |
| MY164230A (en) | Levocarrimycin, Pharmaceutical Compositions, Preparation Methods and Uses Thereof | |
| WO2007122581A3 (en) | Compositions and kits of phenylephrine | |
| TR200806298A2 (tr) | Farmasötik formülasyon | |
| CO6470841A2 (es) | Preparación de sólido que presenta propiedad de disolución mejorada de un medicamento a partir de la misma | |
| EA201491937A1 (ru) | Инъецируемая композиция | |
| BR112013030068A2 (pt) | grânulos de controle biológico estabilizados dispersíveis em água | |
| CL2014002896A1 (es) | Una formulacion farmaceutica en la forma de una tableta recubierta que consiste de a) un nucleo obtenido a partir de una co-mezcla de manitol, croscarmelosa de sodio y al menos un compuestos activo, y b) un recubrimiento el cual se aplica en la forma de una solucion acuosa o que contiene agua y alcohol, y donde la tableta se desintegra rapidamente en presencia de humedad; y su proceso de preparacion. | |
| ECSP11010856A (es) | Composición farmacéutica sólida | |
| BR112015014092A2 (pt) | administração oral transmucosal de acetato de glatirâmer | |
| BR112014004753A2 (pt) | formulação de liberação de multicamadas | |
| FR2945535B1 (fr) | Compose anticancereux et composition pharmaceutique le contenant | |
| CL2007000765A1 (es) | Combinaciones de principios activos que contienen al menos un compuesto derivado de pirazol carboxamida y otro principio activo; procedimiento de preparacion; procedimiento de aplicacion; y uso para combatir hongos fitopatogenos indeseados. | |
| CY1112501T1 (el) | Φαρμακευτικες συνθεσεις περιεχουσες λεφλουνομιδη | |
| BR112014010564A2 (pt) | composições melhoradas | |
| AR081619A1 (es) | Combinacion de principios activos que contiene azadiractina y un compuesto de enaminocarbonilo sustituido |